Alpa Laboratorie

Why is Alpa Laboratories Ltd falling/rising?

As of 16-Aug, Alpa Laboratories Ltd's stock price is 63.23, reflecting a decline of -5.15% and an overall negative performance with a year-to-date drop of -18.30%. The stock is trading below all moving averages, indicating a bearish trend despite increased investor participation.

As of 16-Aug, Alpa Laboratories Ltd is experiencing a decline in its stock price, currently at 63.23, which reflects a change of -3.43 (-5.15%). The stock has been underperforming significantly, with a consecutive fall over the last four days, resulting in a total decline of -8.36% during this period. Today, the stock opened with a loss of -4.56% and reached an intraday low of Rs 62.3, marking a decrease of -6.54%.<BR><BR>In the broader context, Alpa Laboratories has shown negative performance across various time frames. Over the past week, the stock has decreased by -6.69%, while it has fallen -11.44% over the past month. Year-to-date, the decline stands at -18.30%, and over the past year, the stock has dropped -32.66%. Comparatively, the Sensex has shown positive returns in some of these periods, highlighting the stock's underperformance relative to the market.<BR><BR>Additionally, the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 36.9% against the 5-day average, the overall sentiment remains negative, contributing to the stock's decline.

Which are the latest news on Alpa Laboratorie?

Should I buy, sell or hold Alpa Laboratories Ltd?

Who are in the management team of Alpa Laboratorie?

The management team of Alpa Laboratorie includes Mahendra Singh Chawla (Chairman & Executive Director), Pravin C Shah (Executive Director), Paresh Chawla (Managing Director), and several independent directors, along with a Company Secretary. This diverse team oversees the company's operations and governance.

The management team of Alpa Laboratorie includes the following individuals:<BR><BR>1. **Mahendra Singh Chawla** - Chairman & Executive Director<BR>2. **Pravin C Shah** - Executive Director<BR>3. **Paresh Chawla** - Managing Director<BR>4. **Sharad Chand Lunawat** - Independent Director<BR>5. **Devendra Baheti** - Independent Director<BR>6. **Krishna Das Malani** - Independent Director<BR>7. **Jyoti Jain** - Independent Director<BR>8. **Swati Bagh** - Company Secretary & Compliance Officer<BR>9. **Vitthal Kothana** - Executive Director<BR>10. **Sunil Valecha** - Additional Director<BR>11. **Saket Baheti** - Independent Director<BR>12. **Pratibha Lunawat** - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, along with a company secretary, overseeing the operations and governance of the company.

What does Alpa Laboratorie do?

Alpa Laboratories Ltd is a micro-cap pharmaceutical company founded in 1967, specializing in manufacturing pharmaceutical formulations. As of March 2026, it reported net sales of 31 Cr and a net profit of 1 Cr, with a market cap of INR 143 Cr.

Overview: <BR>Alpa Laboratories Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacture of pharmaceutical formulations.<BR><BR>History: <BR>Alpa Laboratories was formed in 1967 and incorporated as a Private Limited Company on March 18, 1988. It was converted into a Public Limited Company on September 3, 1998. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 31 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 143 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.73 <BR>Return on Equity: 7.97% <BR>Price to Book: 0.76 <BR><BR>Contact Details: <BR>Address: 33/2 Pigdamber, A B Road Rau Indore Madhya Pradesh : 453446 <BR>Tel: 91-731-4294567 <BR>Email: is@alpalabs.com <BR>Website: http://www.alpalabs.in

Who are the peers of the Alpa Laboratorie?

Alpa Laboratorie's peers include Parnax Lab, Auro Labs, Smruthi Organic, Bal Pharma, Lactose (India), Kimia Bioscien, Krebs Biochem, Quest Laborato, and Balaxi Pharma. In terms of performance, Lactose (India) leads with a 1-year return of 6.88%, while Alpa Laboratorie has a return of -30.89%.

Peers: The peers of Alpa Laboratorie are Parnax Lab, Auro Labs., Smruthi Organic, Bal Pharma, Lactose (India), Kimia Bioscien., Krebs Biochem, Quest Laborato., and Balaxi Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Parnax Lab and Quest Laborato., while Average management risk is found at Auro Labs., Smruthi Organic, Alpa Laboratorie, Bal Pharma, and Balaxi Pharma, and Below Average management risk is noted at Lactose (India), Kimia Bioscien. and Krebs Biochem. Good growth is seen at Parnax Lab and Quest Laborato., while Below Average growth is present at Auro Labs., Smruthi Organic, Alpa Laboratorie, Bal Pharma, Balaxi Pharma, and Kimia Bioscien., and Good growth is noted at Lactose (India). Excellent capital structure is found at Parnax Lab, Alpa Laboratorie, Quest Laborato., and Balaxi Pharma, while Below Average capital structure is observed at Auro Labs., Bal Pharma, Lactose (India), and Kimia Bioscien., and Krebs Biochem does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Lactose (India) at 6.88%, while the peer with the lowest is Kimia Bioscien. at -33.05%. Alpa Laboratorie’s 1-year return is -30.89%, which is significantly lower than Lactose (India) and higher than Kimia Bioscien. Additionally, the six-month returns for Kimia Bioscien. and Krebs Biochem are negative.

Are Alpa Laboratories Ltd latest results good or bad?

Alpa Laboratories Ltd's latest results are concerning, with a 13.21% decline in net profit and a 21.34% drop in revenue year-on-year, despite improved operating margins. The company's significant underperformance compared to the pharmaceutical sector and reliance on volatile income raise doubts about its future growth prospects.

Alpa Laboratories Ltd's latest results indicate a challenging situation for the company. In Q4 FY26, the net profit was ₹1.38 crore, which represents a decline of 13.21% compared to the previous quarter. Revenue for the same quarter was ₹31.40 crore, reflecting a significant year-on-year drop of 21.34% from ₹39.92 crore in Q4 FY25. Although the operating margin improved to 11.46%, the overall financial performance is concerning due to the substantial revenue contraction.<BR><BR>The company has struggled with declining sales efficiency, as evidenced by a five-year EBIT growth rate of negative 193.44%. Additionally, Alpa Laboratories has underperformed the broader pharmaceutical sector significantly, with its stock price falling 31.77% over the past year while the sector gained 9.25%. <BR><BR>Despite returning to profitability, the reliance on volatile other income raises questions about the sustainability of this profitability. The absence of institutional investor interest and the company's low valuation multiples suggest that the market has serious concerns about its future growth prospects. <BR><BR>In summary, while there are some positive aspects, such as improved operating margins, the overall results reflect a troubling trend for Alpa Laboratories, indicating a challenging outlook ahead.

How big is Alpa Laboratorie?

As of 14th August, Alpa Laboratories Ltd has a market capitalization of 136.55 Cr, with recent net sales of 110.64 Cr and a net profit of 4.06 Cr. Shareholder's funds are 171.43 Cr, and total assets amount to 222.63 Cr as of March 2025.

As of 14th August, Alpa Laboratories Ltd has a market capitalization of 136.55 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, Alpa Laboratories reported Net Sales of 110.64 Cr and a Net Profit of 4.06 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 171.43 Cr and Total Assets of 222.63 Cr.

When is the next results date for Alpa Laboratories Ltd?

The next results date for Alpa Laboratories Ltd is 14 August 2026.

The next results date for Alpa Laboratories Ltd is scheduled for 14 August 2026.

Is Alpa Laboratorie overvalued or undervalued?

As of November 17, 2025, Alpa Laboratorie is considered overvalued and risky, with a PE Ratio of 9.02 and significant underperformance compared to peers like Sun Pharma and Cipla, as well as a year-to-date return of -33.37% against the Sensex's 8.72%.

As of 17 November 2025, the valuation grade for Alpa Laboratorie has moved from very attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 9.02, an EV to EBIT of -9.06, and an EV to EBITDA of -29.26, which suggest that the company's earnings and cash flows are under pressure.<BR><BR>In comparison to its peers, Alpa Laboratorie shows a stark contrast with Sun Pharma, which has a PE Ratio of 36.69 and an EV to EBITDA of 24.22, and Cipla, with a PE Ratio of 22.81 and an EV to EBITDA of 16.14. These comparisons highlight that Alpa Laboratorie is lagging behind its industry counterparts in terms of valuation metrics. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -33.37% compared to the Sensex's 8.72%, reinforcing the notion of its overvaluation.

How has been the historical performance of Alpa Laboratorie?

Alpa Laboratorie has shown steady growth in net sales and profit from Mar'20 to Mar'25, with net sales increasing from 85.97 Cr to 112.45 Cr, and profit before tax rising from 2.54 Cr to 25.67 Cr. Despite fluctuations in operating profit margins and rising raw material costs, the company's total assets and cash flow from operations have significantly improved.

Answer:<BR>The historical performance of Alpa Laboratorie shows a steady growth in net sales and profit over the years, with significant fluctuations in operating profit margins and expenses.<BR><BR>Breakdown:<BR>Alpa Laboratorie's net sales increased from 85.97 Cr in Mar'20 to 112.45 Cr in Mar'25, with a notable rise from 92.44 Cr in Mar'23 to 108.74 Cr in Mar'24. The total operating income followed a similar trend, reaching 112.45 Cr in Mar'25. However, raw material costs have also risen significantly, from 49.48 Cr in Mar'21 to 70.72 Cr in Mar'25, contributing to total expenditure growth from 82.62 Cr in Mar'20 to 107.70 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 10.69 Cr in Mar'22 before dropping to 4.75 Cr in Mar'25. Profit before tax increased from 2.54 Cr in Mar'19 to 25.67 Cr in Mar'25, while profit after tax rose from 0.93 Cr in Mar'19 to 19.50 Cr in Mar'25, indicating improved profitability. The company's total assets grew from 120.43 Cr in Mar'20 to 222.63 Cr in Mar'25, with total liabilities also increasing from 120.43 Cr to 222.63 Cr in the same period. Cash flow from operating activities improved significantly to 18.00 Cr in Mar'25, compared to just 3.00 Cr in Mar'24, reflecting better operational efficiency. Overall, Alpa Laboratorie's financial performance demonstrates a positive growth trajectory despite rising costs and fluctuating profit margins.

Who are the top shareholders of the Alpa Laboratorie?

The top shareholders of Alpa Laboratorie include promoter Paresh Chawla with 34.26%, individual investors with 37.28%, and two foreign institutional investors holding 0.36%. There are no mutual funds or pledged promoter holdings in the company.

The top shareholders of Alpa Laboratorie are primarily its promoters, with Paresh Chawla being the individual with the highest holding at 34.26%. Additionally, individual investors collectively hold 37.28% of the shares. There are also two foreign institutional investors (FIIs) that hold a combined total of 0.36%. Notably, there are no mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Alpa Laboratorie?

As of June 5, 2025, Alpa Laboratorie's trend has shifted to bearish with moderate strength, driven by bearish MACD and moving averages, along with mixed signals from Bollinger Bands and KST.

As of 5 June 2025, the technical trend for Alpa Laboratorie has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and mildly bearish signals from Bollinger Bands and Dow Theory on both weekly and monthly time frames. The KST shows a mildly bullish trend on the weekly but remains mildly bearish monthly, indicating mixed signals. Overall, the bearish trend is reinforced by the recent price action and the performance relative to the Sensex.

Has Alpa Laboratorie declared dividend?

No Dividend History Available